Hydrocarbon-stapled and halogenated helical peptides targeting the CETP self-binding site showed over 5-fold improved binding affinity and effective competitive potency for atherosclerosis therapy.
>5-foldimprovement in binding affinity for CETP self-binding site with stapled/halogenated peptides
What the researchers found
Stapled/halogenated helical peptides achieved >5-fold improved binding affinity for the CETP self-binding site compared to native peptide. Stapling reduced conformational disorder in free state without perturbing binding mode, enhancing competitive potency.
Why it matters
CETP inhibitors have been a long-sought target for treating atherosclerosis. This peptide-based approach offers a new strategy targeting CETP's self-binding mechanism rather than its active site, potentially achieving different and complementary effects to existing small-molecule inhibitors.
The numbers in context
Designed stapled/halogenated peptides showed favorable binding to CETP self-binding site in simulations.
How the study worked
Molecular dynamics simulation for peptide design. Hydrocarbon-stapling optimization based on helical pattern and binding mode. Circular dichroism for helicity measurement. Fluorescence assay for binding affinity. Computational structural examination.
Who was studied
Molecular dynamics simulations of CETP-peptide interactions
What this study cannot tell us
Computational and in vitro study — no cellular or animal model testing. The therapeutic window between CETP inhibition benefit and potential adverse effects needs evaluation. Clinical delivery of stapled peptides for cardiovascular disease presents challenges.
How to read the evidence
Computational design validated by in vitro biophysical assays. Proof-of-concept for peptide approach but no biological or clinical data yet.
When this study was published
Published in 2020. CETP inhibitor research continues with interest in novel targeting strategies.
The bigger picture
Small-molecule CETP inhibitors have had mixed clinical results despite strong rationale. Peptide-based approaches targeting a different binding site could provide an alternative therapeutic strategy for managing cardiovascular risk through cholesterol metabolism modulation.
Questions still open
- Do these stapled peptides effectively inhibit CETP cholesterol transfer activity in vivo?
- How would cardiovascular outcomes compare between peptide-based and small-molecule CETP inhibitors?
- Can stapled peptides be formulated for oral or subcutaneous cardiovascular therapy?
Common questions
What is CETP?
Why use stapled peptides for heart disease?
Read the original research
Molecular modeling and rational design of hydrocarbon-stapled/halogenated helical peptides targeting CETP self-binding site: Therapeutic implication for atherosclerosis.
Journal of molecular graphics & modelling, 94, 107455
Citation
Zhu, Jian; Wei, Sen; Huang, Linchen; Zhao, Qi; Zhu, Haichao; Zhang, Anwei. (2020). Molecular modeling and rational design of hydrocarbon-stapled/halogenated helical peptides targeting CETP self-binding site: Therapeutic implication for atherosclerosis.. Journal of molecular graphics & modelling, 94, 107455. https://doi.org/10.1016/j.jmgm.2019.107455